5th Jan 2017 12:00
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Mereo BioPharma to Present at Biotech Showcase™ in San Francisco on 10 January 2017
London, 5 January 2017 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, is pleased to announce that Denise Scots-Knight, Chief Executive Officer of Mereo will present at Biotech Showcase™ 2017, to be held 9-11 January 2017 in San Francisco, CA.
Mereo BioPharma Presentation Details
Date: Tuesday, 10 January 2017
Time: 11:00 AM PT (7:00 PM GMT)
Location: Hilton San Francisco Union Square, San Francisco, CA 94102
Track & Room: Room 3
For Further Enquiries:
Mereo BioPharma Group plc | +44 (0)333 023 7319 |
Denise Scots-Knight, Chief Executive Officer |
|
|
|
Nominated Adviser and Joint Broker Cantor Fitzgerald Europe | +44 (0)20 7894 7000 |
Phil Davies |
|
Will Goode |
|
|
|
Joint Broker RBC Capital Markets | +44 (0)20 7653 4000 |
Rupert Walford |
|
|
|
Public Relations Adviser to Mereo Biopharma FTI Consulting | +44 (0)20 3727 1000 |
Ben Atwell |
|
Simon Conway |
|
Brett Pollard |
|
About Mereo
Mereo is a UK-based biopharmaceutical company focused on the development of innovative medicines that aim to address unmet medical needs in rare and specialty disease areas and improve patient quality of life. The Company seeks to selectively acquire development-stage product candidates with demonstrated clinically meaningful data from large pharmaceutical companies and to rapidly progress these product candidates to subsequent value inflection points.
Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. The Company has the option to directly commercialise products, for example in orphan diseases, in addition to partnering or divesting its products.
Mereo's initial portfolio consists of three mid-late stage clinical assets that were acquired from Novartis in July 2015. BPS-804 is being developed for the prevention of fractures resulting from osteogenesis imperfecta (brittle bone disease); acumapimod (BCT-197), is being developed to treat inflammation in patients with an acute exacerbation of chronic obstructive pulmonary disease; and BGS-649 is a once-weekly pill to restore normal testosterone levels in men with hypogonadotropic hypogonadism.
In H1 2016 the Company initiated a Phase 2 study with acumapimod and a Phase 2b study with BGS-649. Mereo expects to commence the first pivotal trial for BPS-804 during H1 2017. Additional product opportunities, from a range of large pharmaceutical and biotechnology companies, are under active evaluation.
Related Shares:
MPH.L